Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model

Abstract excerpt

mutations, which constitutively activate the MAPK signaling pathway. We sought to determine whether ERK inhibitor (GDC-0994)-containing regimens may be of clinical benefit to these patients based on data from in vitro (cell line) and in vivo (cell- and patient-derived xenograft) studies of cetuximab (EGFR), vemurafenib (BRAF), cobimetinib (MEK), and GDC-0994 (ERK) combinations. Preclinical data was used to...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Colorectal Cancer Treatments and Studies
• Share to Cytokine Signaling Pathways and Interactions
• Share to Melanoma and MAPK Pathways